InvestorsHub Logo
icon url

tw0122

06/09/23 7:27 AM

#53 RE: 81vette #52

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL